论文部分内容阅读
目的探讨诺和灵30R及诺和锐30治疗2型糖尿病的疗效差异。方法选择本院2型糖尿病患者共80例,随机分为观察组和对照组。观察组给予诺和锐30,对照组给予诺和灵30R治疗,观察两组患者血糖控制情况及不良反应发生情况。结果观察组治疗后的餐后2 h血糖水平、糖化血红蛋白水平低于对照组治疗后,差异有统计学意义(P<0.05)。观察组患者治疗过程中低血糖发生共1例,发生率为2.5%;对照组治疗过程中低血糖发生共8例,发生率为20.0%。观察组患者每天胰岛素用量低于对照组,观察组患者的低血糖发生率低于对照组,差异有统计学意义(P<0.05)。结论诺和锐30治疗2型糖尿病疗效显著,低血糖发生率低,优于诺和灵30R。
Objective To investigate the difference of the curative effect between Novo-30R and Novo-Rui 30 in the treatment of type 2 diabetes mellitus. Methods A total of 80 patients with type 2 diabetes in our hospital were randomly divided into observation group and control group. The observation group was given NovoRui 30 and the control group was given Novolin 30R for treatment. The control of blood glucose and adverse reactions in both groups were observed. Results After treatment, the blood glucose level and the level of HbA1c in the observation group after treatment were lower than those in the control group (P <0.05). A total of 1 hypoglycemia occurred in the observation group during the course of treatment, with a rate of 2.5%. In the control group, a total of 8 cases of hypoglycemia occurred during the course of treatment, with a rate of 20.0%. Insulin consumption in observation group was lower than that in control group. The incidence of hypoglycemia in observation group was lower than that in control group (P <0.05). Conclusion Novo-Rui 30 treatment of type 2 diabetes significant effect, low incidence of hypoglycemia, superior to norepinephrine 30R.